1. Home
  2. Approved trials
  3. » فارسی

The effect of phytosomal curcumin supplementation on inflammation, length of stay and 28-day mortality in multiple trauma patients admitted to the intensive care unit (ICU): a double-blind randomized controlled clinical trial

View the latest revision

History
# Registration date Revision Id
3 2023-01-15, 1401/10/25 252813
2 2022-02-23, 1400/12/04 218888
1 2021-01-12, 1399/10/23 167064
Changes made to previous revision

  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents

  • Protocol summary

    in this double-blind randomized clinical trial study, 50 patients aged 20 to 60 years with multiple trauma admitted to the intensive care unit (ICU) of Al-Zahra Hospital are randomly divided into two groups after having inclusion criteria:
    in this double-blind randomized clinical trial study, 50 patients aged 18 to 70 years with multiple trauma admitted to the intensive care unit (ICU) of Al-Zahra Hospital are randomly divided into two groups after having inclusion criteria:
    در این مطالعه کارآزمایی بالینی تصادفی دوسوکور، 50 بیمار 20 تا 60 ساله مبتلا به مولتیپل تروما بستری در بخش مراقبت های ویژه (ICU) بیمارستان الزهرا (س) پس از دارا بودن معیارهای ورود به طور تصادفی در دو گروه قرار می گیرند:
    در این مطالعه کارآزمایی بالینی تصادفی دوسوکور، 50 بیمار 18-70 ساله مبتلا به مولتیپل تروما بستری در بخش مراقبت های ویژه (ICU) بیمارستان الزهرا (س) پس از دارا بودن معیارهای ورود به طور تصادفی در دو گروه قرار می گیرند:
    Participants: 50 patients aged 20 to 60 years with multiple trauma admitted to the intensive care unit (ICU) Inclusion criteria: , gastrointestinal tract with normal function and intestinal nutrition criteria, diagnosis of sepsis based on blood culture and approval of an ICU and anesthesiologist and infectious disease specialist Exclusion criteria: Impossibility of intestinal nutrition in the first 48 hours of admission, any history of underlying heart disease, patients who are hospitalized in the intensive care unit for less than 48 hours. Patients who are expected to die within 12 hours of admission to the intensive care unit. Patients with BMI <18.5kg / m2 admitted to the intensive care unit. Patients who receive nutritional support with complete intravenous feeding.
    Participants: 50 patients aged 18 to 70 years with multiple trauma admitted to the intensive care unit (ICU) Inclusion criteria: , gastrointestinal tract with normal function and intestinal nutrition criteria, diagnosis of sepsis based on blood culture and approval of an ICU and anesthesiologist and infectious disease specialist Exclusion criteria: Impossibility of intestinal nutrition in the first 48 hours of admission, any history of underlying heart disease, and patients who are hospitalized in the intensive care unit for less than 48 hours. Patients who are expected to die within 12 hours of admission to the intensive care unit. Patients with BMI <18.5kg / m2 were admitted to the intensive care unit. Patients who receive nutritional support with complete intravenous feeding.
    شرکت کنندگان: 50 بیمار 20 تا 60 ساله مبتلا به مولتیپل تروما بستری در بخش مراقبت های ویژه (ICU) شرایط ورود: سن 20-60 سال، دستگاه گوارش با عملکرد نرمال و دارای معیارهای تغذیه روده ای، تشخیص سپسیس بر اساس کشت خون و تایید یک پزشک فوق تخصص ICU و بیهوشی و متخصص عفونی شرایط عدم ورود: عدم امکان تغذیه روده ای در 48 ساعت اول پذیرش، هر نوع سابقه بیماری قلبی زمینه ای، بیمارانی که کمتر از 48 ساعت در بخش مراقبت های ویژه بستری باشند. بیمارانی که پیش بینی می شود ظرف 12 ساعت از پذیرش در بخش مراقبت های ویژه فوت کنند. بیمارانی با نمایه توده بدنی کوچکتر از 18.5 که در بخش مراقبت های ویژه پذیرش می شوند. بیمارانی که تحت حمایت تغذیه ای به روش تغذیه وریدی کامل قرار می گیرند.
    شرکت کنندگان: 50 بیمار 18-70 ساله مبتلا به مولتیپل تروما بستری در بخش مراقبت های ویژه (ICU) شرایط ورود: سن 18-70 سال، دستگاه گوارش با عملکرد نرمال و دارای معیارهای تغذیه روده ای، تشخیص سپسیس بر اساس کشت خون و تایید یک پزشک فوق تخصص ICU و بیهوشی و متخصص عفونی شرایط عدم ورود: عدم امکان تغذیه روده ای در 48 ساعت اول پذیرش، هر نوع سابقه بیماری قلبی زمینه ای، بیمارانی که کمتر از 48 ساعت در بخش مراقبت های ویژه بستری باشند. بیمارانی که پیش بینی می شود ظرف 12 ساعت از پذیرش در بخش مراقبت های ویژه فوت کنند. بیمارانی با نمایه توده بدنی کوچکتر از 18.5 که در بخش مراقبت های ویژه پذیرش می شوند. بیمارانی که تحت حمایت تغذیه ای به روش تغذیه وریدی کامل قرار می گیرند.
    Group 1) Patients receiving placebo, 250 mg capsules of maltodextrin per day for 7 days (n = 25) Group 2) Patients receiving two 250 mg curcumin-phytosomal capsules (total 500 mg daily) for 7 days (25 patients)
    Group 1) Patients receiving two placebos, each capsule contained 250 mg capsules of maltodextrin (total of 500 mg daily) per day for 7 days (n = 25) Group 2) Patients receiving two 250 mg curcumin-phytosomal capsules (total of 500 mg daily) for 7 days (25 patients)
    گروه 1) بیمارانی که به مدت 7 روز دارونما، 2 کپسول 250 میلی گرمی مالتودکسترین در روز دریافت می کنند (25 نفر) گروه 2) بیمارانی که به مدت 7 روز دو کپسول 250 میلی گرم کورکومین-فیتوزومال (در مجموع روزانه 500 میلیگرم) دریافت می کنند (25 نفر)
    گروه 1) بیمارانی که به مدت 7 روز دارونما، 2 کپسول 250 میلی گرمی مالتودکسترین (در مجموع 500 میلیگرم در روز) در روز دریافت می کنند (25 نفر) گروه 2) بیمارانی که به مدت 7 روز دو کپسول 250 میلی گرم کورکومین-فیتوزومال (در مجموع روزانه 500 میلیگرم) دریافت می کنند (25 نفر)

  • General information

    20
    18
    60
    70
    1
    1
    1
    1
    1
    2021-01-20, 1399/11/01
    2021-07-22, 1400/04/31
    2021-02-03, 1399/11/15
    2022-09-21, 1401/06/30
    empty
    Due to assigning the ICU of Al-Zahra Hospital to COVID-19 for a long time, some very minor changes were included in the implementation method.
    empty
    به دلیل اختصاص دادن آی سی یو بیمارستان الزهرا (س) به کوید برای مدت طولانی، برخی تغییرات بسیار جزیی در روش اجرا لحاظ گردید.
    Age 20-60 years
    Gastrointestinal tract with normal function and intestinal nutrition criteria
    Diagnosis of moderate or severe trauma based on GCS index (4-14)
    Trauma diagnosis based on Injury Severity Score (ISS) between minor to severe
    Age 18-70 years
    Gastrointestinal tract with normal function and intestinal nutrition criteria
    Diagnosis of moderate or severe trauma based on GCS index (4-15)
    Trauma diagnosis based on Injury Severity Score (ISS) between minor to severe
    سن 20-60 سال
    دستگاه گوارش با عملکرد نرمال و دارای معیارهای تغذیه روده ای
    تشخیص تروما متوسط یا شدید براساس شاخص GCS (4-14)
    تشخیص تروما بر اساس شاخص Injury Severity Score (ISS) بین سطح minor تا severe
    سن 18-70 سال
    دستگاه گوارش با عملکرد نرمال و دارای معیارهای تغذیه روده ای
    تشخیص تروما متوسط یا شدید براساس شاخص GCS (4-15)
    تشخیص تروما بر اساس شاخص Injury Severity Score (ISS) بین سطح minor تا severe

  • Secondary outcomes

    #1
    Changes in lipid profiles
    Blood sugar changes
    تغییر در پروفایل لیپیدی
    تغییرات قند خون
    #2
    Blood sugar changes
    Serum total protein
    تغییرات قند خون
    توتال پروتئین سرم
    #3
    Serum total protein
    BUN
    توتال پروتئین سرم
    BUN
    ابتدا و انتهای مداخله
    ابتدا وانتهای مداخله
    #4
    BUN
    liver enzymes
    BUN
    آنزیم های کبدی
    #5
    liver enzymes
    Lactate Dehydrogenase (LDH)
    آنزیم های کبدی
    لاکتات دهیدروژناز
    Biochemical test by enzymatic method by Hitachi 902 device
    ELISA method
    آزمایش بیوشیمیایی با روش آنزیماتیک توسط دستگاه هیتاچی 902
    روش الایزا
    #6
    Blood prolactin
    serum albumin
    پرولاکتین خون
    آلبومین سرم
    ELISA method
    Biochemical test by enzymatic method by Hitachi 902 device
    روش الایزا
    آزمایش بیوشیمیایی با روش آنزیماتیک توسط دستگاه هیتاچی 902
    #7
    serum albumin
    Serum creatinine
    آلبومین سرم
    کراتینین سرم
    ابتدا وانتهای مداخله
    ابتدا و انتهای مداخله
    #8
    Serum creatinine
    NUTRIC score
    کراتینین سرم
    نمرهNUTRIC
    ابتدا و انتهای مداخله
    قبل و بعد از مداخله
    Biochemical test by enzymatic method by Hitachi 902 device
    By scoring a questionnaire including APACHE II and SOFA
    آزمایش بیوشیمیایی با روش آنزیماتیک توسط دستگاه هیتاچی 902
    از طریق امتیاز دهی پرسشنامه شامل APACHE II و SOFA
    #9
    NUTRIC score
    empty
    نمرهNUTRIC
    empty
    Before and after the intervention
    empty
    قبل و بعد از مداخله
    empty
    By scoring a questionnaire including APACHE II and SOFA
    empty
    از طریق امتیاز دهی پرسشنامه شامل APACHE II و SOFA
    empty
    #10
    Superoxide dismutase (SOD)
    empty
    سوپراکسید دیسموتاز (SOD)
    empty
    Before and after the intervention
    empty
    قبل و بعد از مداخله
    empty
    Enzymatic method through chemi luminicenece method
    empty
    روش آنزیماتیک از طریق متد chemi luminicenece
    empty
    #11
    Total Antioxidant Capacity (TAC)
    empty
    ظرفیت آنتی اکسیدانی تام (TAC)
    empty
    Before and after the intervention
    empty
    قبل و بعد از مداخله
    empty
    Enzymatic method through chemi luminicenece method
    empty
    روش آنزیماتیک از طریق متد chemi luminicenece
    empty

  • Intervention groups

    #1
    Intervention group: Patients receiving two 250 mg curcumin-phytosomal capsules (total 500 mg daily) for 7 days (25 patients)
    Intervention group: Patients receiving two 250 mg curcumin-phytosomal capsules (total of 500 mg daily) for 7 days (25 patients)
    #2
    Control group: Patients receiving placebo for 7 days, 2 250 mg maltodextrin capsules per day (25 patients)
    Control group: Patients receiving placebo for 7 days, two 250 mg maltodextrin capsules per day (25 patients)

  • Person responsible for general inquiries


    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: saeed abbasi
    Full name of responsible person - Persian: سعید عباسی
    Position - English: Associate Professor
    Position - Persian: دانشیار
    Latest degree: sub_specialist
    Area of specialty/work: 30
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: hezarjarib
    Street address - Persian: هزارجریب
    City - English: esfahan
    City - Persian: اصفهان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8174673461
    Phone: +98 31 3620 1293
    Mobile: +98 913 113 5730
    Fax:
    Email: s_abbasi@med.mui.ac.ir
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Mohammad Bagherniya
    Full name of responsible person - Persian: محمد باقرنیا
    Position - English: Assistant Professor
    Position - Persian: استادیار
    Latest degree: phd
    Area of specialty/work: 34
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: hezarjarib
    Street address - Persian: هزارجریب
    City - English: esfahan
    City - Persian: اصفهان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8174673461
    Phone: +98 31 3620 1293
    Mobile: +98 913 210 1627
    Fax:
    Email: bagherniya@nutr.mui.ac.ir
    Web page address:

  • Person responsible for scientific inquiries


    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: saeed abbasi
    Full name of responsible person - Persian: سعید عباسی
    Position - English: Associate Professor
    Position - Persian: دانشیار
    Latest degree: sub_specialist
    Area of specialty/work: 30
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: hezarjarib
    Street address - Persian: هزارجریب
    City - English: esfahan
    City - Persian: اصفهان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8174673461
    Phone: +98 31 3620 1293
    Mobile: +98 913 113 5730
    Fax:
    Email: s_abbasi@med.mui.ac.ir
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Mohammad Bagherniya
    Full name of responsible person - Persian: محمد باقرنیا
    Position - English: Assistant Professor
    Position - Persian: استادیار
    Latest degree: phd
    Area of specialty/work: 34
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: hezarjarib
    Street address - Persian: هزارجریب
    City - English: esfahan
    City - Persian: اصفهان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8174673461
    Phone: +98 31 3620 1293
    Mobile: +98 913 210 1627
    Fax:
    Email: bagherniya@nutr.mui.ac.ir
    Web page address:

Protocol summary

Study aim
Evaluation of the effect of phytosomal curcumin supplementation in multiple trauma patients admitted to the intensive care unit (ICU): a double-blind randomized controlled clinical trial
Design
This double-blind, randomized trial is performed by Excel software on 50 patients.
Settings and conduct
in this double-blind randomized clinical trial study, 50 patients aged 18 to 70 years with multiple trauma admitted to the intensive care unit (ICU) of Al-Zahra Hospital are randomly divided into two groups after having inclusion criteria:
Participants/Inclusion and exclusion criteria
Participants: 50 patients aged 18 to 70 years with multiple trauma admitted to the intensive care unit (ICU) Inclusion criteria: , gastrointestinal tract with normal function and intestinal nutrition criteria, diagnosis of sepsis based on blood culture and approval of an ICU and anesthesiologist and infectious disease specialist Exclusion criteria: Impossibility of intestinal nutrition in the first 48 hours of admission, any history of underlying heart disease, and patients who are hospitalized in the intensive care unit for less than 48 hours. Patients who are expected to die within 12 hours of admission to the intensive care unit. Patients with BMI <18.5kg / m2 were admitted to the intensive care unit. Patients who receive nutritional support with complete intravenous feeding.
Intervention groups
Group 1) Patients receiving two placebos, each capsule contained 250 mg capsules of maltodextrin (total of 500 mg daily) per day for 7 days (n = 25) Group 2) Patients receiving two 250 mg curcumin-phytosomal capsules (total of 500 mg daily) for 7 days (25 patients)
Main outcome variables
Inflammation, length of stay and mortality 28 days in patients with multiple trauma admitted to ICU

General information

Reason for update
Due to assigning the ICU of Al-Zahra Hospital to COVID-19 for a long time, some very minor changes were included in the implementation method.
Acronym
IRCT registration information
IRCT registration number: IRCT20090306001747N1
Registration date: 2021-01-12, 1399/10/23
Registration timing: prospective

Last update: 2023-01-17, 1401/10/27
Update count: 2
Registration date
2021-01-12, 1399/10/23
Registrant information
Name
Saeed Abbasi
Name of organization / entity
Isfahan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 31 1625 5555
Email address
s_abbasi@med.mui.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-07-22, 1400/04/31
Expected recruitment end date
2022-09-21, 1401/06/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The effect of phytosomal curcumin supplementation on inflammation, length of stay and 28-day mortality in multiple trauma patients admitted to the intensive care unit (ICU): a double-blind randomized controlled clinical trial
Public title
Evaluation of the effect of phytosomal curcumin supplementation in multiple trauma
Purpose
Basic scienece
Inclusion/Exclusion criteria
Inclusion criteria:
Age 18-70 years Gastrointestinal tract with normal function and intestinal nutrition criteria Diagnosis of moderate or severe trauma based on GCS index (4-15) Trauma diagnosis based on Injury Severity Score (ISS) between minor to severe
Exclusion criteria:
Impossibility of intestinal feeding in the first 48 hours of admission Any history of heart disease Patients who are expected to die within 12 hours of admission to the intensive care unit. Patients who do not have an indication for intestinal nutrition on the first day and are confirmed and predicted based on the diagnosis of the intensive care unit and will not be able to receive intestinal nutrition in the future. (Nausea, persistent vomiting, ileus, intestinal obstruction, uncontrolled diarrhea (> 500 ml / day), high-output fistula (> 500 ml / day), intestinal inaccessibility, incomplete resuscitation and hemodynamic instability Patients with BMI <18.5kg / m2 admitted to the intensive care unit. Patients who receive nutritional support through complete intravenous feeding Patients with a history of underlying disease such as diabetes, congenital and immune disorders, renal and hepatic insufficiency, and pancreatitis. Taking anticoagulants such as heparin, warfarin, aspirin, etc. The unwillingness of the patient or his legal guardian to participate in the project Patients who are hospitalized in the intensive care unit for less than 48 hours Pregnancy and lactation Severe septic shock or sepsis
Age
From 18 years old to 70 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 50
Randomization (investigator's opinion)
Randomized
Randomization description
For randomization, the randomized blocking method and spss software will be used, so that according to the sample size, the size of the blocks is 4 and AABB combinations will be used. In the following, all possible modes of the combination of 4 will be listed and for each one, a code will be considered and individuals will be assigned based on them.This will be done using a random number table.
Blinding (investigator's opinion)
Double blinded
Blinding description
In order to this research to be double-blind, at the beginning of the study, a set of cans containing curcumin and placebo supplements that are similar in shape and appearance were coded as A and B by someone other than the researcher, then a person who has no information about supplements and placebo The group that does not know whether it is a supplement or a placebo is poured into cans A and the other group into cans B so that the researchers and participants do not know the type of supplement received by each group.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Isfahan University of Medical Sciences
Street address
hezarjarib
City
isfahan
Province
Isfehan
Postal code
8174673461
Approval date
2020-11-29, 1399/09/09
Ethics committee reference number
IR.MUI.MED.REC.1399.758

Health conditions studied

1

Description of health condition studied
sepsis
ICD-10 code
A41
ICD-10 code description
Other sepsis

Primary outcomes

1

Description
Inflammation
Timepoint
Before and after the intervention
Method of measurement
Measurement of inflammatory markers by serum

2

Description
mortality 28 days
Timepoint
Before and after the intervention
Method of measurement
Use existing statistics

3

Description
Duration of hospitalization
Timepoint
Before and after the intervention
Method of measurement
Use of questionnaire

Secondary outcomes

1

Description
Change in the number of blood cells
Timepoint
Before and after the intervention
Method of measurement
Blood cell count test

2

Description
Blood sugar changes
Timepoint
Before and after the intervention
Method of measurement
Biochemical test by enzymatic method by Hitachi 902 device

3

Description
Serum total protein
Timepoint
Before and after the intervention
Method of measurement
Biochemical test by enzymatic method by Hitachi 902 device

4

Description
BUN
Timepoint
Before and after the intervention
Method of measurement
Biochemical test by enzymatic method by Hitachi 902 device

5

Description
liver enzymes
Timepoint
Before and after the intervention
Method of measurement
Biochemical test by enzymatic method by Hitachi 902 device

6

Description
Lactate Dehydrogenase (LDH)
Timepoint
Before and after the intervention
Method of measurement
ELISA method

7

Description
serum albumin
Timepoint
Before and after the intervention
Method of measurement
Biochemical test by enzymatic method by Hitachi 902 device

8

Description
Serum creatinine
Timepoint
Before and after the intervention
Method of measurement
Biochemical test by enzymatic method by Hitachi 902 device

9

Description
NUTRIC score
Timepoint
Before and after the intervention
Method of measurement
By scoring a questionnaire including APACHE II and SOFA

Intervention groups

1

Description
Intervention group: Patients receiving two 250 mg curcumin-phytosomal capsules (total of 500 mg daily) for 7 days (25 patients)
Category
Treatment - Drugs

2

Description
Control group: Patients receiving placebo for 7 days, two 250 mg maltodextrin capsules per day (25 patients)
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Al-Zahra hospital
Full name of responsible person
Saeed Abbasi
Street address
Sefa Boulevard
City
esfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3668 0042
Email
alikiaiib@med.mui.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shaghayegh Haghjoo
Street address
hezarjarib
City
esfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3668 0042
Email
haghjoo.sh@med.mui.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Mohammad Bagherniya
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
hezarjarib
City
esfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3620 1293
Email
bagherniya@nutr.mui.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Mohammad Bagherniya
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
hezarjarib
City
esfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3620 1293
Email
bagherniya@nutr.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
saeed abbasi
Position
Associate Professor
Latest degree
Subspecialist
Other areas of specialty/work
General Practitioner
Street address
hezarjarib
City
esfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3620 1293
Email
s_abbasi@med.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
All data can be shared after people have requested.
When the data will become available and for how long
Six months after publishing the results.
To whom data/document is available
Academic researchers
Under which criteria data/document could be used
Scientific uses
From where data/document is obtainable
By sending an email to the following address that belongs to the executor of the project s_abbasi@med.mui.ac.ir
What processes are involved for a request to access data/document
Clear request on the site to access the data by the individual and then review the request by the research assistant within 2 weeks and then allow access to the data.
Comments
Loading...